Identification of new candidate drugs for lung cancer using chemical–chemical interactions, chemical–protein interactions and a K-means clustering algorithm
暂无分享,去创建一个
Lei Chen | Tao Huang | Yu-Dong Cai | Yi Bi | Xiangyin Kong | Yu-Dong Cai | Xiangyin Kong | Tao Huang | Lei Chen | Jun Yin | Jing Lu | Mingyue Zheng | Jun Yin | Jing Lu | Mingyue Zheng | Y. Bi
[1] Lei Chen,et al. Prediction of Cancer Drugs by Chemical-Chemical Interactions , 2014, PloS one.
[2] S. Vijayakumar,et al. Prediction of new cyanobacterial drug for treating lung cancer , 2014 .
[3] Jing Lu,et al. A hybrid method for prediction and repositioning of drug Anatomical Therapeutic Chemical classes. , 2014, Molecular bioSystems.
[4] T. Owonikoko,et al. Targeting Angiogenesis in Non-Small Cell Lung Cancer (NSCLC) , 2010 .
[5] Xiaomin Luo,et al. Estimation of acute oral toxicity in rat using local lazy learning , 2014, Journal of Cheminformatics.
[6] Hiroyuki Ogata,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..
[7] Ettinger,et al. Carboplatin in the Treatment of Small Cell Lung Cancer. , 1997, The oncologist.
[8] P. Sunpaweravong,et al. A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer , 2006, Investigational New Drugs.
[9] M. Provencio,et al. The role of anthracyclines in small cell lung cancer. , 2013, Annals of translational medicine.
[10] Canguo Zhao,et al. Expression-Based In Silico Screening of Candidate Therapeutic Compounds for Lung Adenocarcinoma , 2011, PloS one.
[11] Xiao Li,et al. In Silico Prediction of Chemical Acute Oral Toxicity Using Multi-Classification Methods , 2014, J. Chem. Inf. Model..
[12] Kuo-Chen Chou,et al. Predicting Biological Functions of Compounds Based on Chemical-Chemical Interactions , 2011, PloS one.
[13] B. Curry,et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.
[14] J. MacQueen. Some methods for classification and analysis of multivariate observations , 1967 .
[15] S. Lam,et al. The xc− cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine , 2009, Cancer Chemotherapy and Pharmacology.
[16] S. Antonia,et al. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. , 2011, Anticancer research.
[17] G. Tortora,et al. The role of EGFR inhibitors in nonsmall cell lung cancer , 2004, Current opinion in oncology.
[18] Jon A Arnot,et al. Estimating screening-level organic chemical half-lives in humans. , 2014, Environmental science & technology.
[19] F. Ciardiello,et al. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Y. Miyagi,et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors , 2012, Laboratory Investigation.
[21] S. Barry,et al. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. , 2011, International journal of oncology.
[22] T Sahmoud,et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] K. Havemann,et al. Original article: Determining carboplatin/etoposide dosage in extensive stage small-cell lung cancer (SCLC) , 1991 .
[24] Yan Sun,et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.
[25] Lucio Crino,et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Seifried,et al. Prediction of the pathogenicity of antithrombin sequence variations by in silico methods. , 2015, Thrombosis research.
[27] M. P. Goren,et al. Oral mesna: a review. , 1992, Seminars in oncology.
[28] Arlan da Silva Gonçalves,et al. Reactivation steps by 2-PAM of tabun-inhibited human acetylcholinesterase: reducing the computational cost in hybrid QM/MM methods , 2014, Journal of biomolecular structure & dynamics.
[29] M. Kalender,et al. Irinotecan as a second-line monotherapy for small cell lung cancer. , 2011, Asian Pacific journal of cancer prevention : APJCP.
[30] Vijay K. Gombar,et al. Quantitative Structure − Activity Relationship Models of Clinical Pharmacokinetics : Clearance and Volume of Distribution , 2013 .
[31] R. Herbst,et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Dahrouge,et al. A Phase II Study of 5‐Fluorouracil Plus High‐Dose Folinic Acid in the Treatment of Recurrent Small Cell Lung Cancer , 1995, American journal of clinical oncology.
[33] H. Lynch,et al. Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .
[34] Yu-Dong Cai,et al. Finding Candidate Drugs for Hepatitis C Based on Chemical-Chemical and Chemical-Protein Interactions , 2014, PloS one.
[35] Ashalatha Sreshty Mamidi,et al. Hierarchical sampling for metastable conformers determines biomolecular recognition: the case of malectin and diglucosylated N-glycan interactions , 2015, Journal of biomolecular structure & dynamics.
[36] Jonna C. Stålring,et al. Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation. , 2015, Journal of pharmaceutical sciences.
[37] T. Ramalho,et al. Employing conformational analysis in the molecular modeling of agrochemicals: insights on QSAR parameters of 2,4-D , 2013 .
[38] M. Som. Combined therapy. , 1972, JAMA.
[39] Kwangsoo Kim,et al. Mechanistic Insights into the Activation of Oncogenic Forms of EGF Receptor , 2011, Nature Structural &Molecular Biology.
[40] T. Eisen,et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer , 2008, Thorax.
[41] Kumardeep Chaudhary,et al. In Silico Models for Designing and Discovering Novel Anticancer Peptides , 2013, Scientific Reports.
[42] อนิรุธ สืบสิงห์,et al. Data Mining Practical Machine Learning Tools and Techniques , 2014 .
[43] J. Crowley,et al. Teniposide (VM‐26) as a single drug treatment for patients with extensive small cell lung carcinoma , 1997, Cancer.
[44] W Patrick Walters,et al. What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.
[45] Christian von Mering,et al. STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..
[46] Damian Szklarczyk,et al. STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..
[47] K. Kiura,et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. , 2013, Experimental cell research.
[48] R. Jensen,et al. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells , 2005, Peptides.
[49] E. Shimizu,et al. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells. , 2008, Oncology reports.
[50] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[51] A. Rossi,et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] J. Crowley,et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. , 1999, The cancer journal from Scientific American.
[53] Xiaofeng Liu,et al. SHAFTS: A Hybrid Approach for 3D Molecular Similarity Calculation. 1. Method and Assessment of Virtual Screening , 2011, J. Chem. Inf. Model..
[54] M. Fukuoka,et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. , 2006, Anticancer research.
[55] T. Mitsudomi,et al. Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer , 2012, Molecular Cancer Therapeutics.
[56] E. Smit,et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] Alexander Tropsha,et al. Quantitative structure-activity relationship modeling of rat acute toxicity by oral exposure. , 2009, Chemical research in toxicology.